Cedirogant
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 11, 2019 (NCT03922607)
Timeline
Indications
Studied for
Mechanism of action
- Nuclear receptor ROR-gammaINVERSE AGONIST
RORC inverse agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CC1CCN(C(=O)c2ccc(Cl)c(Cn3ccc4cc(C(F)(F)F)cc(Cl)c43)c2Cl)CC1- Mol. weight
- 547.79 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095174 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05376839 | Phase 1 | Jul 6, 2022 | AbbVie |
| NCT05044234 | Phase 2 | Nov 16, 2021 | AbbVie |
| NCT03922607 | Phase 1 | Jun 11, 2019 | AbbVie |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1